文献速递炎症性肠病

美国炎症性肠病3期临床试验可及性的地理不平等

Geographic Inequities in Access to Phase 3 Clinical Trials for Inflammatory Bowel Disease in the United States.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-08-11

该研究旨在地理映射美国炎症性肠病(IBD)3期临床试验的可及性,并识别农村居住和 socioeconomic status 对试验可及性的影响。原文仅报告研究目的,未提供具体方法、样本量或结论。

要点

  • 研究目的是地理映射美国IBD 3期临床试验可及性。
  • 研究旨在识别农村居住和社会经济地位对试验可及性的影响。
  • 原文未报告具体研究结果或结论。

研究设计与样本

  • 研究目的是地理映射美国IBD 3期临床试验可及性,并识别农村居住和社会经济地位对可及性的影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Randomized controlled trials (RCTs) are an important mode of access to treatments for patients with inflammatory bowel diseases (IBDs) (eg, Crohn's disease [CD], ulcerative colitis [UC]), and a critical step in the regulatory process toward the approval of new therapies. Prior studies examining disparities in RCT participation for patients with IBD have importantly focused on racial and age-related disparities.1,2 Lack of geographic access to trials may be an important barrier to participation and a source of inequity. The aim of our study was to geographically map access to phase 3 clinical trials in IBD within the United States, and identify the impact of rural residence and socioeconomic status on access to trials.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Boyd T, Ananthakrishnan AN. Geographic Inequities in Access to Phase 3 Clinical Trials for Inflammatory Bowel Disease in the United States. Clin Gastroenterol Hepatol. 2023. PMID: 37572861. doi:10.1016/j.cgh.2023.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。